Ariad suspends Iclusig sales 'temporarily' on FDA concerns; shares plummet
This article was originally published in Scrip
Executive Summary
Shares of Ariad Pharmaceuticals took another beating on 31 October, spiraling down as low as 45.7%, after the company, at the FDA's request, temporarily suspended the marketing and commercial distribution of the firm’s oral leukemia drug Iclusig (ponatinib) based on reports of serious and life-threatening blood clots and severe narrowing of blood arteries and veins in patients taking the medicine.